Stock Events

Innate Pharma 

€2.22
2
+€0+0% Today

Statistics

Day High
2.22
Day Low
2.22
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
171.81M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.41
-0.27
-0.14
0
Expected EPS
0
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IDD.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap99.17B
Bristol-Myers Squibb competes in the immuno-oncology space, offering products that could be in direct competition with Innate Pharma's pipeline, particularly in cancer treatment.
Merck &
MRK
Mkt Cap318.6B
Merck is known for its strong presence in cancer treatment with Keytruda, competing directly with Innate Pharma's oncology focus.
Roche
RHHBY
Mkt Cap170.92B
Roche operates in similar therapeutic areas as Innate Pharma, including oncology, making it a direct competitor in the development of cancer therapies.
Astrazeneca
AZN
Mkt Cap212.54B
AstraZeneca competes in the oncology sector, including collaborations on drugs that could be in competition with Innate Pharma's developments.
Pfizer
PFE
Mkt Cap147.23B
Pfizer has a broad oncology portfolio that competes with Innate Pharma's cancer treatment and research efforts.
Gilead Sciences
GILD
Mkt Cap83.12B
Gilead Sciences, with its focus on oncology and inflammatory diseases, competes in areas of interest to Innate Pharma.
Novartis
NVS
Mkt Cap206.64B
Novartis has a significant presence in the oncology market, directly competing with Innate Pharma's research and drug development.
AMGEN
AMGN
Mkt Cap144.25B
Amgen's focus on innovative therapeutics in oncology and other areas makes it a competitor to Innate Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap96.81B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on oncology and other areas relevant to Innate Pharma's interests.
Incyte
INCY
Mkt Cap11.75B
Incyte operates in the oncology and inflammation sectors, directly competing with Innate Pharma in the development of treatments for cancer and autoimmune diseases.

About

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Show more...
CEO
Dr. Herve Brailly Ph.D.
Employees
179
Country
FR
ISIN
FR0010331421
WKN
000A0LCUJ

Listings